Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer

Anti-Cancer Drugs ◽

10.1097/00001813-200009000-00005 ◽

2000 ◽

Vol 11 (8) ◽

pp. 629-634 ◽

Author(s):

Michael Hejna ◽

Wolfgang J Köstler ◽

Markus Raderer ◽

Sandra Tomek ◽

Thomas Brodowicz ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Mitomycin C ◽

Phase Ii ◽

Phase Ii Study ◽

Download Full-text

270 A phase II study of oral uracil/ftorafu (UFT) plus leucovorin in combination with mitomycin-C in patients with metastatic colorectal cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90303-x ◽

2003 ◽

Vol 1 (5) ◽

pp. S83

Author(s):

N. Glydenkerne ◽

B. Glimelius ◽

J.-E. Frödin ◽

M. Kjaer ◽

P. Pfeiffer ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Mitomycin C ◽

Phase Ii ◽

Download Full-text

Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

Medical Oncology ◽

10.1007/s12032-019-1254-4 ◽

2019 ◽

Vol 36 (6) ◽

Author(s):

Naoki Nagata ◽

Hiromichi Maeda ◽

Keiichiro Ishibashi ◽

Keiji Hirata ◽

Akitaka Makiyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Wild Type ◽

Randomized Phase Ii

Download Full-text

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3583 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3583-3583 ◽

Author(s):

A. L. A. Fields ◽

D. A. Rinaldi ◽

C. A. Henderson ◽

C. J. Germond ◽

L. Chu ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Second Line ◽

Second Line Therapy ◽

Multicenter Phase ◽

Download Full-text

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

International Journal of Clinical Oncology ◽

10.1007/s10147-015-0943-z ◽

2016 ◽

Vol 21 (4) ◽

pp. 705-712 ◽

Author(s):

Yuji Miyamoto ◽

Akihito Tsuji ◽

Hiroaki Tanioka ◽

Soichiro Maekawa ◽

Hirofumi Kawanaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Chemotherapy ◽

Multicenter Phase ◽

Line Chemotherapy

Download Full-text

276 Promising activity with capecitabine and mitomycin C (MMC) as third line therapy for patients with metastatic colorectal cancer (MCRC) resistant to fluorouracil (5-FU) and irinotecan: results of a phase II study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90309-0 ◽

2003 ◽

Vol 1 (5) ◽

pp. S85

Author(s):

J.L.B. Dickson ◽

S. Rao ◽

M.E. Hill ◽

T.J. Price ◽

A.R. Norman ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Mitomycin C ◽

Phase Ii ◽

Phase Ii Study ◽

Line Therapy ◽

Third Line Therapy ◽

Download Full-text

A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer

Anticancer Research ◽

10.21873/anticanres.13104 ◽

2018 ◽

Vol 39 (1) ◽

pp. 245-252 ◽

Author(s):

MATTHEW R. KEARNEY ◽

EMERSON Y. CHEN ◽

GINA M. VACCARO ◽

JOHN STROTHER ◽

ANDREA BURT ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Download Full-text

CPT-11 and mitomycin-C in heavily pre-treated patients with metastatic colorectal cancer: A Belgian multicentre phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3716 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3716-3716

Author(s):

M. Polus ◽

M. Peeters ◽

F. Baert ◽

P. Vergauwe ◽

H. Kalantari ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Mitomycin C ◽

Phase Ii ◽

Phase Ii Study ◽

Multicentre Phase

Download Full-text

Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

International Journal of Clinical Oncology ◽

10.1007/s10147-017-1212-0 ◽

2017 ◽

Vol 23 (2) ◽

pp. 402-402

Author(s):

Yuji Miyamoto ◽

Akihito Tsuji ◽

Hiroaki Tanioka ◽

Soichiro Maekawa ◽

Hirofumi Kawanaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Chemotherapy ◽

Multicenter Phase ◽

Line Chemotherapy

Download Full-text

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

Annals of Oncology ◽

10.1093/annonc/mdw412 ◽

2016 ◽

Vol 27 (12) ◽

pp. 2216-2224 ◽

Author(s):

M. Moore ◽

S. Gill ◽

T. Asmis ◽

S. Berry ◽

R. Burkes ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Disease Progression ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

Download Full-text

Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

Annals of Oncology ◽

10.1093/annonc/mdx393.047 ◽

2017 ◽

Vol 28 ◽

pp. v177

Author(s):

Y. Mori ◽

N. Suzuki ◽

T. Nagasaka ◽

H. Tanioka ◽

Y. Iwamoto ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Multicenter Phase ◽

Download Full-text